See more : Million Cities Holdings Limited (2892.HK) Income Statement Analysis – Financial Results
Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DigitalBridge Group, Inc. (DBRG-PH) Income Statement Analysis – Financial Results
- JMT Auto Limited (JMTAUTOLTD.NS) Income Statement Analysis – Financial Results
- Cineplex Inc. (CPXGF) Income Statement Analysis – Financial Results
- Yunnan Chihong Zinc & Germanium Co., Ltd. (600497.SS) Income Statement Analysis – Financial Results
- Blue Chip India Limited (BLUECHIP.BO) Income Statement Analysis – Financial Results
AgeX Therapeutics, Inc. (AGE)
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 34.00K | 144.00K | 1.87M | 1.73M | 1.40M | 1.40M |
| Cost of Revenue | 171.00K | 13.00K | 19.00K | 158.00K | 244.00K | 364.00K | 168.00K |
| Gross Profit | -29.00K | 21.00K | 125.00K | 1.71M | 1.48M | 1.03M | 1.24M |
| Gross Profit Ratio | -20.42% | 61.76% | 86.81% | 91.54% | 85.88% | 73.93% | 88.03% |
| Research & Development | 603.00K | 1.03M | 1.46M | 4.98M | 5.90M | 6.63M | 5.78M |
| General & Administrative | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Other Expenses | 11.00K | 13.00K | 448.00K | 44.00K | 294.00K | 183.00K | 38.00K |
| Operating Expenses | 9.93M | 7.00M | 8.16M | 12.38M | 14.04M | 12.28M | 9.65M |
| Cost & Expenses | 10.10M | 7.01M | 8.18M | 12.54M | 14.29M | 12.64M | 9.82M |
| Interest Income | 0.00 | 3.34M | 1.10M | 404.00K | 29.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 3.34M | 1.10M | 0.00 | 0.00 | 116.00K | 0.00 |
| Depreciation & Amortization | 131.00K | 145.00K | 579.00K | 1.68M | 951.00K | 535.00K | 682.00K |
| EBITDA | -9.83M | -6.98M | -7.93M | -9.15M | -11.61M | -10.71M | -9.49M |
| EBITDA Ratio | -6,921.83% | -20,088.24% | -5,180.56% | -481.21% | -671.76% | -767.19% | -675.85% |
| Operating Income | -9.96M | -6.98M | -8.04M | -10.67M | -12.56M | -11.25M | -6.66M |
| Operating Income Ratio | -7,014.08% | -20,514.71% | -5,582.64% | -571.25% | -726.79% | -805.52% | -474.57% |
| Total Other Income/Expenses | -4.85M | -3.55M | -649.00K | 272.00K | 323.00K | 3.51M | 1.78M |
| Income Before Tax | -14.81M | -10.52M | -8.58M | -11.13M | -12.24M | -7.73M | -6.64M |
| Income Before Tax Ratio | -10,430.28% | -30,947.06% | -5,959.72% | -595.61% | -708.10% | -553.80% | -472.72% |
| Income Tax Expense | -8.00K | 152.00K | 1.64M | -150.00K | 148.00K | 3.51M | -1.80M |
| Net Income | -14.80M | -10.67M | -10.22M | -10.98M | -12.38M | -7.50M | -6.58M |
| Net Income Ratio | -10,424.65% | -31,394.12% | -7,097.22% | -587.58% | -716.67% | -537.39% | -468.66% |
| EPS | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
DiagnaMed Expands with Drug and Clinical Research AI Platform
Bitcoin dominance surges as crypto markets show signs of consolidation
QVC DEFINES A NEW AGE OF POSSIBILITY CHAMPIONING WOMEN 50 AND OVER TO LIVE THEIR BEST LIVES
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
Shareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with Serina
Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
Source: https://incomestatements.info
Category: Stock Reports